Jan 7, 2026
1003(a)(i) - Equity below $2 million and years of losses
NYSE American
RESOLVED
On April 2, 2026, Serina Therapeutics announced that NYSE American approved its compliance plan after originally receiving a deficiency notice on January 9, 2026, for failing to meet the minimum stockholders’ equity requirement with reported equity of $1.6 million and historical net losses. Under the approved plan, the company remains listed subject to quarterly monitoring and has until July 9, 2027, to regain full compliance with continued listing standards (Filed At: 2026-04-02).
Jan 8, 2026
1003(a)(ii) - Equity below $4 million and years of losses
NYSE American
RESOLVED
Following a deficiency notice received on January 9, 2026, for having stockholders' equity under $4.0 million alongside historical net losses, Serina Therapeutics received approval from NYSE American for its compliance plan to maintain its listing subject to quarterly monitoring. The company has been granted until July 9, 2027, to regain full compliance with the continued listing standards (Filed At: 2026-04-02).
Jan 7, 2026
1003(a)(ii) - Equity below $4 million and years of losses
NYSE American
RESOLVED
After receiving a non-compliance notice on January 9, 2026, for reporting stockholders' equity of $1.6 million alongside historical net losses, Serina Therapeutics had its plan to regain compliance accepted by NYSE American as announced on April 2, 2026. The company remains listed subject to quarterly monitoring and has until July 9, 2027, to regain full compliance with continued listing standards. Filed At: 2026-04-02
Jan 8, 2026
1003(a)(i) - Equity below $2 million and years of losses
NYSE American
RESOLVED
On April 2, 2026, Serina Therapeutics announced that the NYSE American approved its plan to regain compliance with continued listing standards after receiving a deficiency notice on January 9, 2026, due to reporting stockholders' equity of $1.6 million and historical net losses. The company will remain listed subject to quarterly monitoring and has until July 9, 2027, to regain full compliance (Filed At: 2026-04-02).
